by Manon FRACHON | 24 Mar Mon | English
Proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase 2 proof-of-concept clinical trial in Charcot-Marie-Tooth and support significant pipeline expansion into cardio-metabolic and neurodegenerative diseases. This investment... by Manon FRACHON | 3 Mar Mon | English
Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. Investment will contribute to achieve clinical proof-of-concept for Callio’s HER-2-targeted... by Manon FRACHON | 7 Jan Tue | English
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001, a pioneering transformative gene therapy approach for the treatment of severe cardiovascular disease. This investment builds on Jeito’s expertise in cardiology,... by Manon FRACHON | 7 Jan Tue | English
Investment will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy secondary to age-related macular degeneration (AMD); Aviceda’s ongoing Phase 2b/3 trial evaluating AVD-104 is fully enrolled, with 12-month... by Manon FRACHON | 22 Nov Fri | English
Paris, France, November 22nd 2024 – Jeito is pleased to announce that Dr Rafaèle Tordjman has received L’Agefi’s prestigious 2024 ‘AM Leader’ Award at L’Agefi’s annual “Grands Prix” ceremony. The award recognizes... by Manon FRACHON | 12 Nov Tue | English
Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023) rounds, Jeito’s renewed commitment demonstrates its strategy of supporting promising portfolio companies through key value-creation milestones. Financing will advance...
Recent Comments